drugset / Trial / NCT00047788

Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer

NCT00047788

Phase 2 Completed 30 enrolled Genzyme, a Sanofi Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective is to assess the efficacy of ZD6474 when given orally to patients with relapsed multiple myeloma. A minimum of 15 and a maximum of 30 evaluable patients will be entered on study

Timeline

Start
2002-10
Primary completion
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Vandetanib Small molecule Oral

Indications